TP53 and acute myeloid leukemia: Patients with TP53-mutated (TP53MUT) AML have a lower probability of achieving remission when treated with intensive chemotherapy and, consequently, have poor outcomes; for those who achieve remission, allo-HCT provides a relatively small improvement in long-term survival [2,5,6,7,8,9].